Abiopharma

🔍 Boyd Peter E. (Executive)

Company: Aquestive Therapeutics, Inc. (AQST)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Acquired 80,000 shares of Common Stock (Direct)
  Date: 2026-03-09 | Code: A | equity_swap_involved: false | shares_owned_after: 368,323.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 29,814 shares of Common Stock at $4.173 per share (Direct)
  Date: 2026-03-10 | Code: S | equity_swap_involved: false | shares_owned_after: 338,509.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Acquired 42,500 shares of Non-Qualified Stock Option (right to buy) at $4.29 per share (Derivative)
  Date: 2026-03-09 | Code: A | Expires: 2036-03-09 | equity_swap_involved: false | shares_owned_after: 42,500.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
• F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
• F3: This transaction was executed in multiple trades at prices ranging from $4.17 to $4.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
• F4: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.